The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Just Published

JCP
Biography Inscribed in Biology: Diagnostic Criteria for Psychosomatic Research and the Embodiment of Lived Experience
Commentary

March 25, 2026

The DCPR framework, with its emphasis on allostatic overload, provides evidence that biography becomes biology and that lived experience is inscribed into our physiological systems.
JCP
Mind-Body Integration and East-West Fusion for Modern Medicine: Insights from the Diagnostic Criteria for Psychosomatic Research
Commentary

March 25, 2026

Clinimetrics not only lays the methodological foundation for the promotion of the DCPR but also shows potential in interdisciplinary applications.
,
JCP
What Clinicians Should Know About Alzheimer’s Treatment with Marc Agronin, MD
Podcast

March 24, 2026

Dr. Marc Agronin covers early Alzheimer’s screening, biomarker diagnostics, anti-amyloid immunotherapy, and emerging treatments for cognitive decline
,

Insightful. Evidence-based. Human-centered.

The Journal of Clinical Psychiatry Podcast

Explore the science, practice, and human side of mental health care. Hosted by Dr. Ben Everett, Senior Scientific Director at Physicians Postgraduate Press, the series brings together leading voices in psychiatry, neuroscience, and behavioral medicine to discuss the evidence shaping clinical care today.

Each episode features thoughtful conversations with JCP authors, academic experts, and frontline clinicians exploring disorders across the mental health continuum, from schizophrenia and mood disorders to anxiety, depression, and sleep-related conditions. By bridging research and real-world practice, the podcast delivers insights that empower psychiatrists, nurse practitioners, physician associates, and primary care clinicians to deliver better care for patients with mental illness.

Learn More

 

Explore Special Sections

Focus on Childhood and Adolescent Mental Health Early Career Psychiatrists Focus on Geriatric Psychiatry Focus on Psychotherapy Focus on Psychosis Focus on Suicide Focus on Women’s Mental Health
Cover features March 2026 issue highlighting articles on psychiatric drugs, peer interventions for perinatal depression, and metformin.

Vol 87 • 2026 • Number 1

Read the Current Issue

Original Research

Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024

Meta-Analysis

Effectiveness of Peer-Administered Interventions for Perinatal Depression or Anxiety

Original Research

Effect of Adjuvant Metformin on Adherence to and Persistence of Treatment With SGAs in Nondiabetic Patients

Editorial

Thank You to the JCP Community

Editorial

Psychotherapy: Integral to Clinical Psychiatry

Original Research

Trends in Benzodiazepine Prescribing to Adults in the United States
View current Issue

Original Research

JCP
Neuropsychiatric Symptom Clusters and Brain Structure in Alzheimer’s Disease
Original Research

March 16, 2026

Neuropsychiatric symptoms in Alzheimer’s disease separate into hyperactivity, psychosis, neurovegetative, and affective clusters, supporting a cluster-based paradigm linking behavioral symptoms with brain structure and functional decline.
, , , et al
JCP
Temporal Dynamics of Antidepressant Response Following Brexanolone Treatment in Postpartum Depression
Original Research

March 11, 2026

Temporal-Dynamics-Antidepressant-Response-Brexanolone-Treatment-Postpartum-Depression
, , , et al
JCP
Safety and Efficacy of Maintenance Treatment with Aripiprazole Once-Monthly in Black/African American Adults With Bipolar I Disorder
Original Research

March 9, 2026

The safety and efficacy of AOM 400 were comparable between Black/African American and non-Black/African American patients with bipolar I disorder
, , , et al

Review Articles

JCP
Burnout in Psychiatric Doctors Before and After the COVID-19 Pandemic
Meta-Analysis

September 29, 2025

The prevalence of burnout was 37.5% prior to the COVID-19 pandemic and 32.0% following the pandemic.
, ,
JCP
Treating PTSD in Military Populations
Meta-Analysis

March 24, 2025

Integrating psychotherapies and pharmacotherapies may address multiple dimensions of PTSD more effectively than monotherapies.
, , , et al
JCP
Changes in Cognition in Patients With Schizophrenia
Meta-Analysis

September 25, 2024

Only marginal improvements in cognition were seen over time; the greatest were achieved for patients with an illness duration shorter than 10 years.
, , , et al
JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
, , , et al
JCP
Cognitive Effects of ECT in Schizophrenia: A Review
Review Article

June 5, 2024

ECT was not associated with any significant cognitive deficits in people with treatment-resistant schizophrenia across global cognition, attention, language, visuospatial function, and executive function domains. The majority of studies…
,
JCP
Interpersonal Psychotherapy for PTSD: A Critical Review
Review Article

May 29, 2024

This critical review will give clinicians confidence in considering IPT as an alternative to exposure treatments for posttraumatic stress disorder.

Read articles from ASCP Corner

ASCP Corner

Letters to the Editor

JCP
Vitamin B12 Deficiency Risk With Metformin for Weight Management in Second-Generation Antipsychotic Recipients: Reply to Mulsant et al
Letter to the Editor

March 18, 2026

Daggolu and Chen reply to a letter commenting on their study of metformin use in patients receiving second-generation antipsychotics.
,
JCP
Concurrent Metformin and Second-Generation Antipsychotics: The Need to Add Vitamin B12
Letter to the Editor

March 18, 2026

The authors recommend vigilance for potential B12 deficiency when coprescribing metformin and antipsychotics.
, ,
JCP
Neural Dysconnectivity and Affective Disorders: Integrating Sleep and Emotional Regulation Perspectives
Letter to the Editor

March 16, 2026

The authors discuss sleep disturbance in the context of recent research on functional dysconnectivity in the brain’s triple networks.
, , , et al
JCP
Triple Network Dysconnectivity and Sleep Disturbance in Young People With Suicidal Ideation: Reply to Ferruzzi et al
Letter to the Editor

March 16, 2026

Cheng et al reply to a letter regarding their recent study of triple network functional dysconnectivity in major affective disorders.
, ,
JCP
Rationale for Clozapine Trial
Letter to the Editor

January 28, 2026

Dr Mattes comments on a recent article examining the use of clozapine versus other antipsychotic options.
JCP
The Position of Clozapine in Patients with Treatment-Resistant Schizophrenia: Reply to Mattes
Letter to the Editor

January 28, 2026

Dr Andrade replies to a letter about his article on factors affecting choice of clozapine versus other antipsychotics.

Commentaries

JCP
Benzodiazepines as Special Risk Medications
Commentary

February 18, 2026

In light of a study examining current benzodiazepine prescribing trends, Dr Silberman comments on appropriate clinical use of these medications.
JCP
Precision Medicine for Suicide Prevention: It’s Time to Take the Next Step
Commentary

December 22, 2025

The authors recommend moving toward a precision medicine approach to suicide prevention that considers the person, their circumstances and biology, treatment delivery context, and conditions that contribute to the…
, , , et al
JCP
The Goldilocks Problem: Balancing Internal Validity with Generalizability in Clinical Trials
Commentary

November 26, 2025

The author discusses a recent analysis by Zimmerman and Snyder focusing on the generalizability of PTSD treatment trials.
JCP
MAOI Antidepressants: A History Being Rewritten
Commentary

November 26, 2025

Members of the International MAOI Expert Group discuss historical use of MAOIs, consider their efficacy and safety, and underscore the importance of reassessing their place in treatment algorithms.
, , , et al
JCP
Gender-Affirming Perinatal Psychiatry for Transgender and Gender Diverse People
Commentary

November 10, 2025

Considerations for providing perinatal psychiatric care to transgender and gender diverse patients are addressed
, ,
JCP
Beyond the Boxed Warning: A Call for Regulation of Psychiatry’s Most Teratogenic Drug
Commentary

October 6, 2025

The authors assert that while valproate remains invaluable for certain severe conditions, the high risk of teratogenicity means stringent safeguards are needed to regulate its use by individuals capable…
, , , et al

More JCP Articles

JCP
Association of SSRIs and Other Antidepressants With Dental Implant Failure
Clinical and Practical Psychopharmacology

March 18, 2026

Antidepressant users should be educated about the risk of dental implant failure, and efforts should be made to identify and negate other risk factors for implant failure.
JCP
Life After Clozapine: Managing Treatment-Resistant Schizophrenia When Clozapine Is No Longer an Option
ASCP Corner

March 11, 2026

The authors discuss treatment options and reinitiation of clozapine following clozapine discontinuation.
,
JCP
Behind the Manuscript: Inpatient Treatment of Suicidality with Brett Jones, MD, MSc, PhD, FRCPC
Podcast

March 10, 2026

Dr. Brett Jones reviews evidence-based interventions for inpatient suicidality: ketamine, chronotherapy, and dialectical behavior therapy for acute psychiatric care.
,
JCP
Efficacy of Olanzapine/Samidorphan on Negative Symptoms
Original Research

March 9, 2026

Olanzapine/samidorphan was associated with significant and durable improvement in negative symptoms of schizophrenia, overall and among patients with prominent and predominant negative symptoms.
, , , et al
JCP
Comparing Risk Prediction for Suicide Attempts and Deaths After Emergency Department Visits
Original Research

March 4, 2026

Distinct factors predict nonfatal and fatal suicidal events. Male sex and depression are the strongest predictors for fatal events; being under 65 years of age and suicidal ideation are…
, , , et al
JCP
Outcomes and Practice Patterns of LAI Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the US
Original Research

March 2, 2026

Long-acting injectable antipsychotics, especially second-generation formulations, are associated with reduced rehospitalization in bipolar I disorder compared to oral antipsychotics.
, , , et al
JCP
How Sleep Issues Show Up in Psychiatric Practice with Dr. Avinesh Bhar, CEO of SLIIIP
Podcast

February 24, 2026

Sleep medicine specialist Dr. Avinesh Bhar discusses how sleep-disordered breathing drives psychiatric and cardiometabolic morbidity, the clinical case for integrating sleep evaluation into mental health care, and how home…
,
JCP
Oral Glutamatergic Modulation with Dextromethorphan and Piracetam for Refractory Bipolar Disorder With OCD
Case Report

February 23, 2026

Three patients with combined bipolar disorder and OCD experienced remission of depressive, anxious, and obsessive-compulsive symptoms after piracetam was added to dextromethorphan.
JCP
Effects of Extended Cannabis Abstinence in Comorbid PTSD and Cannabis Use Disorder
Original Research

February 18, 2026

Participants who achieved abstinence reported significantly greater reductions in total PTSD symptom severity and symptom count compared to those who did not.
, , , et al
JCP
Postmarketing Safety of Transcranial Magnetic Stimulation: A 10-Year MAUDE Database Analysis
Original Research

February 11, 2026

This study addresses a key postmarket gap by analyzing real-world TMS adverse event reports from the MAUDE database.
, , , et al
JCP
The E-value in Regression
Clinical and Practical Psychopharmacology

February 11, 2026

This article provides a primer on the E-value and explains its calculation and interpretation.
JCP
Clinical pearls of early use of Xanomeline–Trospium in the in-patient setting with Michael Halassa MD, PhD
Podcast

February 10, 2026

Dr. Halassa shares clinical insights on xanomeline-trospium for inpatient schizophrenia, addressing negative symptoms and treatment-resistant cases.
,

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe